Atossa Therapeutics staples one contingent value right to each common share
ATOS•Atossa Therapeutics common shares will carry one contingent value right each as of the October 19, 2026, close. Holders collectively may receive 25% of net proceeds from the first qualifying priority review voucher’s sale or deemed monetization, capped at $50 million.
1. CVR terms
Atossa Therapeutics common stock will carry one stapled contingent value right (CVR) per share at the October 19, 2026, close of business. The CVRs will transfer only with their corresponding shares unless the board elects to detach them for separate trading; shares issued later will also carry one CVR until detachment or expiration of the CVR Agreement. Holders collectively will receive 25% of net proceeds from the sale or deemed monetization of the first qualifying priority review voucher, capped at $50 million. The voucher must be awarded by December 31, 2036, subject to a board extension.
